Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum

NCT ID: NCT00573885

Last Updated: 2012-03-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-01-31
• Study Completion Date: 2008-12-31

Brief Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. Green tea extract may keep cancer from forming.

PURPOSE: This randomized phase II trial is studying green tea extract in preventing cancer in former and current heavy smokers with abnormal sputum.

Detailed Description

OBJECTIVES:

• Evaluate the efficacy and safety of defined green tea catechin extract (polyphenon E) in former smokers with abnormal sputum score using stringent, newly developed response criteria of combined nuclear morphometry and malignancy-associated changes as the primary surrogate endpoint.
• Evaluate if polyphenon E can modulate other surrogate endpoint biomarkers of aberrant methylation, cell cycle regulation, apoptosis, oncogene/tumor suppressor gene expression, as well as phase I and II enzyme regulation.
• Establish a library of in-vivo confocal micro-endoscopy and optical coherent tomography images of the bronchial epithelium with corresponding histopathology, nuclear morphometry, and other biomarker information to assess the potential of confocal micro-endoscopy as a non-biopsy method to assess the effect of chemoprevention agents.

OUTLINE: This is an open label, part 1 study followed by a randomized, double-blind, part 2 study.

• Part 1 (completed March 22, 2006): Patients receive oral defined green tea catechin extract twice daily in months 1 and 2 and inhaled budesonide twice daily in month 2.

Patients undergo autofluorescence bronchoscopy with biopsies, oral and bronchial brushing, and bronchoalveolar lavage at the end of months 1 and 2.

• Part 2: Patients are stratified by gender and randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral defined green tea catechin extract twice daily for 6 months.
• Arm II: Patients receive oral placebo twice daily for 6 months. Patients who have progressive or stable disease at 6 months may receive open-label defined green tea catechin extract.

Patients undergo autofluorescence bronchoscopy with biopsies, oral and bronchial brushing, and bronchoalveolar lavage at the end of months 6 and 12.

Blood samples are collected periodically for biomarker studies. After completion of study therapy, patients are followed periodically for 6 months.

Conditions

Lung Cancer; Tobacco Use Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Arm I

Patients receive oral defined green tea catechin extract twice daily for 6 months.

Group Type: EXPERIMENTAL

defined green tea catechin extract

Intervention Type: DRUG

Given orally

Arm II

Patients receive oral placebo twice daily for 6 months.

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: OTHER

Given orally

Interventions

defined green tea catechin extract

Given orally

Intervention Type: DRUG

placebo

Given orally

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• ECOG performance status 0-1
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Creatinine normal
• Bilirubin normal
• AST and ALT normal
• Alkaline phosphatase normal

Exclusion Criteria

• Chronic active hepatitis/liver cirrhosis
• Severe heart disease (e.g., unstable angina, chronic congestive heart failure, use of antiarrhythmic agents)
• Ongoing gastric ulcer
• Acute bronchitis or pneumonia within one month
• Known reaction to lidocaine, albuterol sulfate, midazolam hydrochloride, and/or alfentanil hydrochloride
• Known allergy to green tea and/or corn starch, gelatin, or other nonmedicinal ingredients
• Any medical condition, such as acute or chronic respiratory failure or bleeding disorder that, in the opinion of the investigator, could jeopardize the patient's safety during participation in the study
• Unwilling to have a bronchoscopy
• Unwilling to have a spiral chest CT

PRIOR CONCURRENT THERAPY:

• No more than 5 cups of tea a week
• No concurrent anticoagulant treatment such as warfarin or heparin
• No use of other natural health products containing green tea compounds

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 74 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

University of Cincinnati

OTHER

Sponsor Role: collaborator

British Columbia Cancer Agency

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Stephen Lam, MD

Role: STUDY_CHAIR

British Columbia Cancer Agency

Locations

British Columbia Cancer Agency - Vancouver Cancer Centre

Vancouver, British Columbia, Canada

Countries

Canada

Other Identifiers

P01CA096964

Identifier Type: NIH

Identifier Source: secondary_id

View Link

BCCA-H03-61083

Identifier Type: -

Identifier Source: secondary_id

BCCA-R03-1083

Identifier Type: -

Identifier Source: secondary_id

CDR0000578191

Identifier Type: -

Identifier Source: org_study_id